Search Result
Results for "
ICR mice
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-N2542
-
-
-
- HY-160926
-
|
Glutathione S-transferase
|
Cancer
|
16-Oxocafestol enhances levels of glutathione S-transferase (GST) and tissue sulfhydryl in liver and in small bowel mucosa .
|
-
-
- HY-W012977
-
-
-
- HY-W008151
-
|
Mitochondrial Metabolism
|
Metabolic Disease
|
Diphenyl Phosphate inhibits growth and energy metabolism in zebrafish and mice in a sex-specific manner. Diphenyl Phosphate can inhibit the activity of SDH (respiratory complex II), reduce the expression of CPT1 and disrupts the integrity of the mitochondrial membrane. Diphenyl Phosphate may be used in research on metabolic diseases .
|
-
-
- HY-N14350
-
|
Bacterial
|
|
Hydroxychlorothricin is an antibiotic of the chlorothricin group. Hydroxychlorothricin can be found in Streptomyces sp. K818. Hydroxychlorothricin has anti-tumor effect and can prolong the survival period of ICR mice inoculated with Ehrlich cancer cells .
|
-
-
- HY-115826
-
|
Biochemical Assay Reagents
|
Cancer
|
AB-163 is an alkylating agent with anti-tumor activity. AB-163 exerts LD50s of 198 (p.o.) and 159 (i.p.) mg/kg in ICR/Ha male mice and can be utilized in cancer research .
|
-
-
- HY-163315
-
|
Keap1-Nrf2
AMPK
|
Metabolic Disease
|
YPLP is a yeast-derived peptide Tyr-Pro-Leu-Pro, which exhibits activity in anti fatigue mechanisms through the nuclear factor erythroid-2-related factor 2 (Nrf2)- and AMP-activated protein kinase (AMPK) pathway. YPLP is orally active .
|
-
-
- HY-N2542R
-
|
Reference Standards
Interleukin Related
NO Synthase
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Tubeimoside III (Standard) is the analytical standard of Tubeimoside III (HY-N2542). This product is intended for research and analytical applications. Tubeimoside III is a triterpenoid saponin. Tubeimoside III has anti-inflammatory and antitumor effects. Tubeimoside III has an LD50 of 15 mg/kg by intraperitoneal injection in ICR mice. Tubeimoside III can be used for the research of tumors and inflammatory diseases .
|
-
-
- HY-158365
-
|
LRRK2
|
Neurological Disease
|
LRRK2-IN-14 (Compound 8) is an orally active LRRK2 inhibitor. LRRK2-IN-14 has an IC50 of 6.3 nM for LRRK2(G2019S) cell activity.LRRK2-IN-14 has an inhibitory effect on hERG (IC50=22 μM). LRRK2-IN-14 has blood-brain barrier permeability .
|
-
-
- HY-162407
-
|
Btk
|
Cancer
|
I-As-1 is a potent inhibitor of Bruton’s tyrosine kinase (BTK), with the IC50 of 2.35 nM. I-As-1 shows antiproliferative activities among Ramos cells and OCI-LY10 cells with IC50s of 0.52 μM and 0.11 μM, respectively .
|
-
-
- HY-162764
-
|
Androgen Receptor
|
Cancer
|
Androgen receptor degrader-5 (compound 14k) exhibits promising properties, including superior androgen receptor degradation activity and antiproliferative activity .
|
-
-
- HY-113556
-
-
-
- HY-146468
-
|
Dipeptidyl Peptidase
GPR119
Potassium Channel
|
Metabolic Disease
|
DPP-4/GPR119 modulator 1 (Compound 22) is an orally active dipeptidyl peptidase IV (DPP-IV) inhibitor and GPR119 agonist. DPP-4/GPR119 modulator 1 shows blood glucose-lowering effect and moderate inhibition on hERG channel with an IC50 of 4.9 μM. DPP-4/GPR119 modulator 1 can be used for diabetes research . DPP-4/GPR119 modulator 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-152031
-
|
Amyloid-β
|
Neurological Disease
|
Glutaminyl Cyclase Inhibitor 5 (Compound 71) is a potent and selective human glutaminyl cyclase (hQC) inhibitor with an IC50 of 3.2 nM .
|
-
-
- HY-129246
-
|
DNA/RNA Synthesis
|
Cancer
|
Cytembena is inhibitor for replicative DNA synthesis, purine synthesis and tetrahydrofolate formylase activity. Cytembena ameliorates ovarian or breast cancer, relieves the pain from skeletal metastases .
|
-
-
- HY-168651
-
|
FBPase
|
Metabolic Disease
|
FBPase-IN-4 (Compound 11 n) is a potent FBPase (Fructose-1,6-bisphosphatase) inhibitor with a Ki value of 1.78 μM. FBPase-IN-4 can be used in type 2 diabetes research .
|
-
-
- HY-34596
-
|
Biochemical Assay Reagents
Amyloid-β
|
Neurological Disease
Metabolic Disease
|
4-Hydroxyindole is a type of hydroxyindole in which the 1H-indole at position 4 is substituted by a hydroxyl group.
4-Hydroxyindole serves as an important raw material or intermediate in the synthesis of pharmaceutical products and industrial polymers.
4-Hydroxyindole inhibits amyloid fibrillization and induces liver function impairment, thyroid abnormalities, and blood glucose fluctuations in mice.
4-Hydroxyindole holds potential for research in neurodegenerative diseases and metabolic disorders .
|
-
-
- HY-146615
-
|
TAM Receptor
|
Cancer
|
Axl-IN-6 (compound 14) is an orally active and potent AXL inhibitor. Axl-IN-6 is well tolerated and significantly inhibits the tumor growth in MV-4-11 subcutaneous xenograft model .
|
-
-
- HY-158113
-
|
Histone Acetyltransferase
PROTACs
|
Cancer
|
CBPD-409 is an orally active PROTAC degrader for CBP/p300, with DC50 of 0.2–0.4 nM. CBPD-409 exhibits antiproliferative effects in AR+ prostate cancer cell lines VCaP, LNCaP and 22Rv1, with IC50s of 1.2–2.0 nM. CBPD-409 exhibits antitumor efficacy (Red: CBP inhibitor GNE049 (HY-108435); Blue: CRBN/cullin 4A Thalidomide (HY-14658); Black: Linker) .
|
-
-
- HY-115996
-
|
Apoptosis
|
Cancer
|
Antitumor agent-51 possesses potent and selective inhibitory for osteosarcoma cell growth and migration with IC50 of 21.9 nM in MNNG/HOS cells. Antitumor agent-51 has a considerable bioavailability and a low toxicity .
|
-
-
- HY-171758
-
|
Opioid Receptor
|
Neurological Disease
|
BU72 is a highly potent and long-acting agonist of μ and κ opioid receptors, and also has a partial agonist effect on δ opioid receptors (EC50 values are 0.054, 0.033, and 0.58 nM, respectively). BU72 has a strong and long-lasting analgesic effect, which is mainly mediated by μ opioid receptors. BU72 has a long-lasting activity and can partially reverse the analgesic effect of morphine. BU72 can be used in the study of opioid dependence .
|
-
-
- HY-174381
-
|
Cholinesterase (ChE)
Amyloid-β
Tau Protein
|
Neurological Disease
|
BChE-IN-41 is a highly selective Butyrylcholinesterase (BChE) inhibitor (IC50 =12 nM, Ki = 6.6 nM). BChE-IN-41 has high brain penetration with a brain-to-plasma ratio of 9.0. BChE-IN-41 has pro-cognitive effects on mice with AD-like symptoms induced by Scopolamine (HY-N0296) and Aβ1-42 .
|
-
-
- HY-146715
-
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
IDO/Tubulin-IN-2 (HT2) is a potent TDO and tubulin inhibitor. IDO/Tubulin-IN-2 also shows potent activity against U87, HepG2, A549, HCT-116, and LO2 cancer cell lines, with IC50 values of 0.43, 0.036, 0.041, 0.095 and 1.04 μM, respectively. IDO/Tubulin-IN-2 remarkably promotes the antitumor activity .
|
-
-
- HY-146883A
-
|
Filovirus
|
Infection
|
As-358 (hydrochloride) has inhibitory effects against Ebola virus and Marburg virus with IC50s of 9.1 μM and 18.1 μM, as well as exhibits good in vivo safety .
|
-
-
- HY-147943
-
|
PROTACs
Btk
|
Cancer
|
PROTAC BTK Degrader-1 is a potent, selective and orally active PROTAC BTK degrader with an IC50 value of 34.51 nM and 64.56 nM for BTK WT and BTK-481S, respectively. PROTAC BTK Degrader-1 effectively reduces BTK protein levels and suppresses tumor growth . PROTAC BTK Degrader-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-146619
-
|
Amyloid-β
Serotonin Transporter
|
Neurological Disease
|
RAGE/SERT-IN-1 is a potent and orally active advanced glycation end products (RAGE) and serotonin transporter (SERT) inhibitor with IC50s of 8.26 μM and 31.09 nM, respectively. RAGE/SERT-IN-1 exhibits significant neuroprotective effect against Aβ25-35-induced neuronal damage and alleviates depressive behavior of mice. RAGE/SERT-IN-1 can be used for researching the comorbidity of Alzheimer's disease and depression .
|
-
-
- HY-163505
-
|
Bacterial
|
Others
|
Anti-MRSA agent 11 suppresses fluoroquinolone-sensitive strain USA500 and -resistant MRSA isolate Mu50 (MIC =0.39 μg/mL). Anti-MRSA agent 11 displayes favorable in vivo half-life and safety profiles .
|
-
-
- HY-176706
-
|
AAK1
|
Neurological Disease
|
AAK1-IN-10 (Compound 1-2) is an AAK1 inhibitor. AAK1-IN-10 has significant AAK1 enzyme inhibitory activity (IC50: 9.62 nM). AAK1-IN-10 mainly exerts its effects by inhibiting the activity of connexin-associated kinase 1 (AAK1). AAK1-IN-10 has low cardiotoxicity (IC50 = 13.7 μM). AAK1-IN-10 can be used in the study of diabetic neuropathy and postherpetic pain .
|
-
-
- HY-174221
-
|
IMPDH
HDAC
Apoptosis
|
Cancer
|
IMPDH II/HDAC1-IN-1 (Compound C12) is an orally active dual-target inhibitor of IMPDH II and IMPDH II (IC50 values are 84.69 nM and 81.75 nM, respectively). IMPDH II/HDAC1-IN-1 has significant anti-tumor activity and has an anti-proliferative effect on K-562 cells (IC50 = 305.31 nM). IMPDH II/HDAC1-IN-1 exerts a synergistic anti-tumor effect by simultaneously targeting IMPDH II and HDAC1, inhibiting tumor cell proliferation and inducing apoptosis. IMPDH II/HDAC1-IN-1 can be used in the study of cancers such as chronic myeloid leukemia (CML) .
|
-
-
- HY-139414
-
|
Interleukin Related
p38 MAPK
ERK
Apoptosis
|
Inflammation/Immunology
|
Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). Lysophosphatidylcholines induces cell injury, the production of IL-1β and apoptosis. Lysophosphatidylcholines has a proactive effect on sepsis .
|
-
-
- HY-N0815
-
Resibufogenin
Maximum Cited Publications
6 Publications Verification
Bufogenin; Recibufogenin
|
PI3K
Akt
NF-κB
AP-1
GSK-3
CDK
|
Neurological Disease
Inflammation/Immunology
Cancer
|
Resibufogenin is an orally active anticancer agent. Resibufogenin can be extracted from toad venom. Resibufogenin blocks signaling pathways such as PI3K/Akt, NF-κB, AP-1, activates GSK-3β, and regulates cyclin D1. Resibufogenin can activate central neurons. Resibufogenin has anti-inflammatory activity. Resibufogenin has anti-tumor effects on a variety of tumors such as multiple myeloma, renal cancer, colorectal cancer, pancreatic cancer, and glioma .
|
-
-
- HY-143586
-
|
CDK
|
Cancer
|
CDK7-IN-8 is a potent CDK7 inhibitor with IC50 of 54.29 nM. CDK7-IN-8 has inhibitory effect on certain cancer cells and in vivo tumor models .
|
-
-
- HY-162633
-
|
Deubiquitinase
|
Cancer
|
USP1-IN-9 (Compound 1m) is reversible and noncompetitive ubiquitin-specific proteases (USP1) inhibitors with an IC50 of 8.8 nM, which is designed and synthesized to pyrido[2,3-d]pyrimidin-7(8H)-one derivative based on the disclosed structure of ML323(HY-17543) and KSQ-4279(HY-145471). USP1-IN-9 displays excellent USP1/UAF inhibition and exhibits strong antiproliferation effect in breast cancer cells. USP1-IN-9 can generate enhanced cell killing with PARP inhibitor olaparib(HY-10162) in olaparib-resistant MDA-MB-436/OP cells, which is promising for research in the field of cancer .
|
-
-
- HY-Y0946
-
|
Biochemical Assay Reagents
|
Inflammation/Immunology
Cancer
|
Acetamide is used as an intermediate in the synthesis of methylamine, thioacetamide, and insecticides, and as a plasticizer in leather, cloth and coatings. Acetamide has carcinogenicity. Acetamide derivatives may has antioxidant activity and potential anti-inflammatory activity. Acetamide holds promise for research in the fields of anti-inflammatory and cancer studies .
|
-
-
- HY-145845
-
|
HDAC
Monoamine Oxidase
|
Neurological Disease
|
HDAC1/MAO-B-IN-1 is a potent, selective and cross the blood-brain barrier HDAC1/MAO-B inhibitor with IC50 values of 21.4 nM and 99.0 nM for HDAC1 and MAO-B, respectively. HDAC1/MAO-B-IN-1 has the potential for the research of Alzheimer’s disease .
|
-
-
- HY-Y0946R
-
|
Biochemical Assay Reagents
Reference Standards
|
Inflammation/Immunology
Cancer
|
Acetamide (Standard) is the analytical standard of Acetamide. This product is intended for research and analytical applications. Acetamide is used as an intermediate in the synthesis of methylamine, thioacetamide, and insecticides, and as a plasticizer in leather, cloth and coatings. Acetamide has carcinogenicity. Acetamide derivatives may has antioxidant activity and potential anti-inflammatory activity. Acetamide holds promise for research in the fields of anti-inflammatory and cancer studies .
|
-
-
- HY-174802
-
|
Cyclic GMP-AMP Synthase
IKK
IFNAR
|
Inflammation/Immunology
|
XL-3158 is a selective and cross-species Cyclic GMP-AMP synthase (cGAS) inhibitor (IC50: 11.1 μM for human cGAS, 2.19 μM for mouse cGAS). XL-3158 simultaneously occupy allosteric and orthosteric sites, stabilizing the activation loop in a closed, inactive conformation and thereby attenuating the cGAS-DNA interactions. XL-3158 inhibits cGAS by targeting phase separation. XL-3158 efficiently penetrates cells by inhibiting aggregate formation, effectively reducing the local concentration of cGAS within cells. XL-3158 has no obvious cytotoxicity within the effective concentration range and is suitable for subsequent cell function experiments. XL-3158 overcomes species selectivity barriers and serves as a drug candidate for cGAS-dependent inflammatory diseases.
|
-
-
- HY-162600
-
|
CDK
|
Inflammation/Immunology
|
CDK8-IN-15 (Compound 46) is a potent CDK8 inhibitors with an IC50 value of 57 nM. It can enhance the thermal stability of CDK8 along with inhibition against NF-κB and have favourable selectivity across the CDK family and tyrosine kinase. Additionally, it also demostrates a positive effect in vitro psoriasis model induced by TNF-α and alleviats the inflammatory response enhancing the expression of Foxp3 and IL-10, which is promising for research of psoriasis diseases .
|
-
-
- HY-176128
-
|
PROTACs
Androgen Receptor
Molecular Glues
|
Cancer
|
BWA-6047 is a dual AR/AR-V7 and GSPT1 PROTAC degrader (AR: DC50 = 3.7 nM; AR-V7: DC50 = 3.0 nM; GSPT1: DC50 = 1.2 nM). BWA-6047 promotes ubiquitination and degradation of AR/AR-V7 and, through its molecular glue properties, induces the formation of a PPI between GSPT1 and CRBN, leading to GSPT1 degradation. BWA-6047 can be used in prostate cancer research (Pink: AR/AR-V7 ligand (HY-176129); Blue: E3 CRBN ligand (HY-W069604); Black: linker (HY-W069604)) .
|
-
-
- HY-176732
-
|
Epigenetic Reader Domain
|
Cancer
|
MJ-26 is an inhibitor targeting Menin. MJ-26 has high binding affinity (Ki: 0.56 μM) and significant antiproliferative activity. MJ-26 works by inhibiting Menin-MLL interaction and inducing Menin protein degradation. MJ-26 has significant antitumor effects on acute myeloid leukemia (AML). MJ-26 can be used in AML research .
|
-
-
- HY-147395
-
|
GPR52
|
Neurological Disease
|
GPR52 agonist-1 is a potent, orally active and blood-brain barrier (BBB) penetrant GPR52 agonist with an pEC50 value of 7.53. GPR52 agonist-1 affects cAMP accumulation through direct interaction with GPR52. GPR52 agonist-1 can significantly suppress Methamphetamine-induced hyperactivity in mice. Antipsychotic activity .
|
-
-
- HY-146672
-
|
Itk
|
Cancer
|
ITK inhibitor 6 (compound 43) is a potent and selective ITK inhibitor with IC50s of 4 nM, 133 nM, 320 nM, 2360 nM, 155 nM for ITK, BTK, JAK3, EGFR, LCK, respectively. ITK inhibitor 6 inhibits phosphorylation of PLCγ1 and ERK1/2. ITK inhibitor 6 shows antiproliferative activities .
|
-
-
- HY-143434
-
|
FLT3
|
Cancer
|
FLT3/D835Y-IN-1 (compound 13a) is a orally active, potent and selective FLT3 and FLT3/D835Y inhibitor, with IC50 values of 0.26 nM and 0.18 nM, respectively. FLT3/D835Y-IN-1 also blocks tumor growth, has anticancer efficacy, and can be used to research for AML (acute myeloid leukemia) .
|
-
-
- HY-173428
-
|
Fungal
|
Infection
|
Antifungal agent 130 (Compound A7) is an orally active antifungal agent. Antifungal agent 130 has good antifungal activity against Candida albicans (MIC = 0.12 ng/mL) and Cryptococcus neoformans (MIC = 0.12 ng/mL) and has excellent antivirulence effect. Antifungal agent 130 exerts its antifungal effect by disrupting the iron homeostasis of fungal cells and inducing oxidative stress damage. Antifungal agent 130 can inhibit the formation of fungal virulence factors (such as biofilm, capsule, urease and melanin). Antifungal agent 130 has good antifungal effect and can be used in the study of drug-resistant fungal infections .
|
-
-
- HY-143414
-
|
Beta-lactamase
Bacterial
|
Infection
|
Metallo-β-lactamase-IN-6 is a potent VIM-Type metallo-β-lactamase inhibitor with IC50s of 0.56 μM, 29.50 μM and 5.78 μM for VIM-2, VIM-1 and VIM-5. Metallo-β-lactamase-IN-6 displays potent synergistic antibacterial activity with Meropenem against engineered Escherichia coli strains and intractable clinically isolated Pseudomonas aeruginosa producing VIM-2 MBL .
|
-
-
- HY-172903
-
|
Sodium Channel
|
Neurological Disease
Inflammation/Immunology
|
Nav1.8-IN-16 (Compound (R)-40) is an orally active and selective hNaV 1.8 inhibitor (IC50: 5.9 nM). Nav1.8-IN-16 exerts analgesic effects by blocking NaV1.8 channels without significantly affecting other NaV subtypes or hERG channels. Nav1.8-IN-16 exhibits dose-dependent analgesic effects in postoperative pain and inflammatory pain models and can be used in pain-related research .
|
-
-
- HY-144658
-
|
Factor Xa
|
Cardiovascular Disease
|
FXIa-IN-8 is a potent and selective FXIa inhibitor with an IC50 of 14.2 nM. FXIa-IN-8 shows antithrombotic activity without increasing the bleeding risk and obvious toxicitysup>[1].
|
-
-
- HY-149844
-
|
Fungal
|
Infection
|
S-F24 is an antifungal agent with excellent broad-spectrum. S-F24 inhibits CYP3A4 with an IC50 value of 0.4 μM. S-F24 displays a good safety profile with high selectivity, low hemolytic effects, and low tendency to induce resistance. S-F24 can be used for research on fungal infections .
|
-
-
- HY-163403
-
|
VEGFR
|
Cardiovascular Disease
Cancer
|
VEGFR-2-IN-43 (compound 16) is an orally active inhibitor of VEGFR2, with an IC50 of 39.91 μM. VEGFR-2-IN-43 can be used for wet age-related macular degeneration (w-AMD) disease research .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-139414
-
|
Cell Assay Reagents
|
Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). Lysophosphatidylcholines induces cell injury, the production of IL-1β and apoptosis. Lysophosphatidylcholines has a proactive effect on sepsis .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-163315
-
|
Keap1-Nrf2
AMPK
|
Metabolic Disease
|
YPLP is a yeast-derived peptide Tyr-Pro-Leu-Pro, which exhibits activity in anti fatigue mechanisms through the nuclear factor erythroid-2-related factor 2 (Nrf2)- and AMP-activated protein kinase (AMPK) pathway. YPLP is orally active .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: